{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-157307","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.551637+00:00","generated_at":"2026-06-14T10:42:32.316257+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TScan Therapeutics prices $140M public offering of common stock and pre-funded warrants","bullets":["Gross proceeds of ~$140M from 22.99M shares at $2.00/share and 47.01M pre-funded warrants at $1.9999 each.","Net proceeds estimated at $134.7M after underwriting discounts and expenses.","Underwriters granted 30-day option to purchase up to 10.5M additional shares.","Proceeds for general corporate purposes; existing cash plus offering expected to fund operations into 2026.","Offering closed May 31 for shares and June 1 for warrants; Morgan Stanley and Wedbush lead."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-157307","json":"https://secwatch.observer/filing/0001193125-23-157307.json","markdown":"https://secwatch.observer/filing/0001193125-23-157307.md","text":"https://secwatch.observer/filing/0001193125-23-157307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523157307/0001193125-23-157307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523157307/d476076d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:42:32.316257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54ba22209b9a02526fc847638064094d9e74dc7c","claim":"TScan Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Wedbush Securities Inc., as representatives (effective 2023-05-25).","evidence_excerpt":"On May 25, 2023, TScan Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC and Wedbush Securities Inc., as representatives (the “ Representatives ”) of the underwriters named therein","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523157307/0001193125-23-157307-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Morgan Stanley & Co. LLC and Wedbush Securities Inc., as representatives"},{"label":"Effective","value":"2023-05-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}